Vγ9Vδ2-T cells as antigen presenting cells for iNKT cell based cancer immunotherapy.
CD1d-restricted invariant natural killer T cells (iNKT) constitute an important immunoregulatory T-cell subset involved in the induction of antitumor immune responses. Here, we provide a view on the recent observation that Vγ9Vδ2-T cells, through trogocytosis of CD1d-containing membrane fragments, have the capacity to act as antigen presenting cells for iNKT.
Department of Medical Oncology; VU University Medical Center ; Amsterdam, The Netherlands.
Inge M
IM
Werter
Department of Medical Oncology; VU University Medical Center ; Amsterdam, The Netherlands.
Famke L
FL
Schneiders
Institut National de la Santé et de la Recherche Médicale; UMR892; Center de Recherche en Cancérologie Nantes-Angers ; Nantes Cedex, France.
Emmanuel
E
Scotet
Department of Medical Oncology; VU University Medical Center ; Amsterdam, The Netherlands.
Henk M W
HM
Verheul
Department of Medical Oncology; VU University Medical Center ; Amsterdam, The Netherlands.
Tanja D
TD
de Gruijl
Department of Medical Oncology; VU University Medical Center ; Amsterdam, The Netherlands.
Hans J
HJ
van der Vliet
APC; APC, antigen presenting cells; Ag, antigens; BTN, butyrophilin; BrHPP, bromohydrin pyrophosphate; CD, Cluster of differentiation; CD1d; DN, double negative; GM-CSF, granulocyte-macrophage colony-stimulating factor; IFNγ, interferon γ; IL, interleukine; IPP, isopentenyl pyrophosphate; MHC, major histocompatibility complex; NK, natural killer cells; PBMC, peripheral blood mononuclear cells; TNFα, tumor necrosis factor α; Th1, Type 1 T helper; Th2, Type 2 T helper; Vγ9Vδ2-T cells; i.v., intravenous; iNKT; iNKT, invariant natural killer T cells; moDC, monocyte derived dendritic cells; pAg, phosphoantigens; trogocytosis; α-GalCer, α-galactosylceramide